Partager
Back

INNOVATIVE PRODUCTS

Spotlight

60
new molecules and vaccines in clinical development, of which 17 are in Phase III trials or currently being considered for market authorization (as of Feb. 2012).

5
new products submitted to American and/or European regulatory agencies.

Genzyme is finalizing the regulatory submission for Lemtrada™ (alemtuzumab) to treat patients with relapsing multiple sclerosis. It will be filed in Europe and in the United States in 2012.

In 2011, Jevtana® (cabazitaxel) injection received marketing approval in Europe for the treatment of hormone refractory metastatic prostate cancer (previously treated with docetaxel).

Read more